Symbols / RLYB Stock $13.95 -2.79% Rallybio Corporation

Healthcare • Biotechnology • United States • NCM
RLYB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Stephen Uden M.D., MBBS
Exch · Country NCM · United States
Market Cap 73.79M
Enterprise Value 21.35M
Income -8.98M
Sales 858.00K
FCF (ttm) -20.34M
Book/sh 10.97
Cash/sh 10.35
Employees 14
Insider 10d —
IPO Jul 29, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.58
PEG —
P/S 86.00
P/B 1.27
P/C —
EV/EBITDA -0.68
EV/Sales 24.88
Quick Ratio 12.96
Current Ratio 14.51
Debt/Eq 0.30
LT Debt/Eq —
EPS (ttm) -1.59
EPS next Y -5.40
EPS Growth —
Revenue Growth 4.84%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-05-13
ROA -30.07%
ROE -15.01%
ROIC —
Gross Margin 0.00%
Oper. Margin -28.88%
Profit Margin 0.00%
Shs Outstand 5.29M
Shs Float 3.15M
Insider Own 4.16%
Instit Own 60.80%
Short Float 35.77%
Short Ratio 23.93
Short Interest 1.57M
52W High 15.31
vs 52W High -8.88%
52W Low 2.16
vs 52W Low 545.84%
Beta -1.10
Impl. Vol. —
Rel Volume 0.01
Avg Volume 344.96K
Volume 4.86K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $14.35
Price $13.95
Change -2.79%
About

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$13.95
Latest analyst target
3. DCF / Fair value
$-69.22
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.95
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-04-15 down Jones Trading Buy → Hold —
2025-04-09 down HC Wainwright & Co. Buy → Neutral —
2025-03-17 reit HC Wainwright & Co. Buy → Buy $5
2025-02-12 reit HC Wainwright & Co. Buy → Buy $5
2025-01-13 reit HC Wainwright & Co. Buy → Buy $5
2024-12-03 reit HC Wainwright & Co. Buy → Buy $5
2024-11-22 reit HC Wainwright & Co. Buy → Buy $5
2024-11-08 main HC Wainwright & Co. Buy → Buy $5
2024-10-30 reit HC Wainwright & Co. Buy → Buy $6
2024-10-01 reit HC Wainwright & Co. Buy → Buy $6
2024-09-03 reit HC Wainwright & Co. Buy → Buy $6
2024-08-26 main Evercore ISI Group Outperform → Outperform $15
2024-08-12 main HC Wainwright & Co. Buy → Buy $6
2024-05-15 down JP Morgan Overweight → Neutral —
2024-05-10 reit HC Wainwright & Co. Buy → Buy $9
2024-04-19 reit JMP Securities Market Outperform → Market Outperform $8
2024-04-18 reit JMP Securities Market Outperform → Market Outperform $8
2024-04-11 main Wedbush Outperform → Outperform $11
2024-03-13 reit JMP Securities Market Outperform → Market Outperform $8
2024-03-13 main HC Wainwright & Co. Buy → Buy $9
News
RSS: Latest RLYB news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.86
+34.91%
0.64
0.00
0.00
Operating Revenue
0.86
+34.91%
0.64
0.00
0.00
Operating Expense
33.92
-44.51%
61.13
-22.55%
78.93
+16.27%
67.88
Research And Development
19.60
-52.79%
41.51
-22.48%
53.54
+31.59%
40.69
Selling General And Administration
14.32
-27.01%
19.62
-22.70%
25.39
-6.64%
27.20
General And Administrative Expense
14.32
-27.01%
19.62
-22.70%
25.39
-6.64%
27.20
Other Gand A
14.32
-27.01%
19.62
-22.70%
25.39
-6.64%
27.20
Total Expenses
33.92
-44.51%
61.13
-22.55%
78.93
+16.27%
67.88
Operating Income
-33.06
+45.35%
-60.50
+23.36%
-78.93
-16.27%
-67.88
Total Operating Income As Reported
-33.06
+45.35%
-60.50
+23.36%
-78.93
-16.27%
-67.88
EBITDA
-32.97
+45.38%
-60.37
+23.38%
-78.78
-16.34%
-67.72
Normalized EBITDA
-32.97
+45.38%
-60.37
+23.38%
-78.78
-16.34%
-67.72
Reconciled Depreciation
0.09
-29.77%
0.13
-12.67%
0.15
-10.18%
0.17
EBIT
-33.06
+45.35%
-60.50
+23.36%
-78.93
-16.27%
-67.88
Net Income
-8.98
+84.46%
-57.77
+22.52%
-74.56
-11.87%
-66.65
Pretax Income
-8.98
+84.46%
-57.77
+22.52%
-74.56
-11.87%
-66.65
Net Non Operating Interest Income Expense
2.19
-48.08%
4.22
-31.41%
6.15
+213.14%
1.96
Interest Expense Non Operating
—
—
—
0.00
Net Interest Income
2.19
-48.08%
4.22
-31.41%
6.15
+213.14%
1.96
Interest Expense
—
—
—
0.00
Interest Income Non Operating
2.19
-48.08%
4.22
-31.41%
6.15
+213.14%
1.96
Interest Income
2.19
-48.08%
4.22
-31.41%
6.15
+213.14%
1.96
Other Income Expense
21.90
+1564.68%
-1.50
+15.96%
-1.78
-142.70%
-0.73
Other Non Operating Income Expenses
22.77
+2960.62%
0.74
+183.97%
0.26
-23.39%
0.34
Tax Provision
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-8.98
+84.46%
-57.77
+22.52%
-74.56
-11.87%
-66.65
Net Income From Continuing Operation Net Minority Interest
-8.98
+84.46%
-57.77
+22.52%
-74.56
-11.87%
-66.65
Net Income From Continuing And Discontinued Operation
-8.98
+84.46%
-57.77
+22.52%
-74.56
-11.87%
-66.65
Net Income Continuous Operations
-8.98
+84.46%
-57.77
+22.52%
-74.56
-11.87%
-66.65
Normalized Income
-8.98
+84.46%
-57.77
+22.52%
-74.56
-11.87%
-66.65
Net Income Common Stockholders
-8.98
+84.46%
-57.77
+22.52%
-74.56
-11.87%
-66.65
Diluted EPS
-1.59
+85.06%
-10.64
+27.72%
-14.72
+11.96%
-16.72
Basic EPS
-1.59
+85.06%
-10.64
+27.72%
-14.72
+11.96%
-16.72
Basic Average Shares
5.63
+3.42%
5.44
+7.66%
5.06
+27.11%
3.98
Diluted Average Shares
5.63
+3.42%
5.44
+7.66%
5.06
+27.11%
3.98
Diluted NI Availto Com Stockholders
-8.98
+84.46%
-57.77
+22.52%
-74.56
-11.87%
-66.65
Earnings From Equity Interest
-0.87
+60.96%
-2.24
-9.70%
-2.04
-89.86%
-1.07
Earnings From Equity Interest Net Of Tax
—
—
—
-1.07
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
62.26
-8.58%
68.11
-41.09%
115.62
-35.92%
180.44
Current Assets
61.25
-9.71%
67.84
-40.90%
114.79
-36.05%
179.50
Cash Cash Equivalents And Short Term Investments
54.74
-16.45%
65.51
-40.41%
109.93
-34.95%
168.99
Cash And Cash Equivalents
31.37
+125.66%
13.90
-43.24%
24.49
-57.00%
56.96
Other Short Term Investments
23.36
-54.73%
51.61
-39.59%
85.44
-23.74%
112.04
Prepaid Assets
4.00
+199.63%
1.33
-52.42%
2.81
-70.31%
9.45
Other Current Assets
2.52
+152.96%
0.99
-51.56%
2.05
+95.62%
1.05
Total Non Current Assets
1.01
+277.53%
0.27
-67.87%
0.83
-11.50%
0.94
Net PPE
0.20
-25.84%
0.27
-54.90%
0.59
-34.87%
0.91
Gross PPE
0.68
-26.38%
0.92
-17.40%
1.11
-13.03%
1.28
Accumulated Depreciation
-0.48
+26.61%
-0.65
-25.05%
-0.52
-40.21%
-0.37
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.17
+15.13%
0.15
-56.07%
0.35
-33.97%
0.52
Machinery Furniture Equipment
0.36
-17.40%
0.43
+0.00%
0.43
+2.62%
0.42
Construction In Progress
—
—
—
0.00
Other Properties
—
—
—
0.52
Leases
0.15
-56.51%
0.34
+0.00%
0.34
+0.00%
0.34
Investments And Advances
—
0.00
-100.00%
0.24
+696.67%
0.03
Long Term Equity Investment
—
0.00
-100.00%
0.24
+696.67%
0.03
Other Non Current Assets
0.81
—
—
—
Total Liabilities Net Minority Interest
4.30
-33.30%
6.45
-31.60%
9.44
-15.13%
11.12
Current Liabilities
4.22
-32.35%
6.24
-32.61%
9.26
-13.78%
10.74
Payables And Accrued Expenses
1.58
-26.20%
2.15
-63.51%
5.88
+0.31%
5.86
Payables
0.13
-54.68%
0.28
-71.52%
0.98
-12.39%
1.11
Accounts Payable
0.13
-54.68%
0.28
-71.52%
0.98
-12.39%
1.11
Current Accrued Expenses
1.46
-21.96%
1.87
-61.91%
4.90
+3.29%
4.75
Pensionand Other Post Retirement Benefit Plans Current
2.33
-24.59%
3.10
-2.24%
3.17
-32.68%
4.70
Current Debt And Capital Lease Obligation
0.09
-38.96%
0.15
-29.68%
0.22
+20.99%
0.18
Current Capital Lease Obligation
0.09
-38.96%
0.15
-29.68%
0.22
+20.99%
0.18
Current Deferred Liabilities
0.21
-75.00%
0.85
0.00
—
Current Deferred Revenue
0.21
-75.00%
0.85
0.00
—
Total Non Current Liabilities Net Minority Interest
0.08
-61.32%
0.21
+22.54%
0.17
-53.74%
0.37
Long Term Debt And Capital Lease Obligation
0.08
0.00
-100.00%
0.17
-53.74%
0.37
Long Term Capital Lease Obligation
0.08
0.00
-100.00%
0.17
-53.74%
0.37
Non Current Deferred Liabilities
0.00
-100.00%
0.21
0.00
—
Non Current Deferred Revenue
0.00
-100.00%
0.21
0.00
—
Stockholders Equity
57.96
-6.00%
61.65
-41.94%
106.18
-37.29%
169.32
Common Stock Equity
57.96
-6.00%
61.65
-41.94%
106.18
-37.29%
169.32
Capital Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Common Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
5.28
+1.82%
5.19
+9.73%
4.73
-0.02%
4.73
Ordinary Shares Number
5.28
+1.82%
5.19
+9.73%
4.73
-0.02%
4.73
Additional Paid In Capital
359.93
+1.50%
354.60
+3.86%
341.41
+3.39%
330.21
Retained Earnings
-302.00
-3.06%
-293.02
-24.56%
-235.25
-46.40%
-160.68
Gains Losses Not Affecting Retained Earnings
0.02
-73.53%
0.07
+353.33%
0.01
+107.01%
-0.21
Other Equity Adjustments
0.02
-73.53%
0.07
+353.33%
0.01
+107.01%
-0.21
Total Equity Gross Minority Interest
57.96
-6.00%
61.65
-41.94%
106.18
-37.29%
169.32
Total Capitalization
57.96
-6.00%
61.65
-41.94%
106.18
-37.29%
169.32
Working Capital
57.03
-7.42%
61.60
-41.63%
105.53
-37.47%
168.75
Invested Capital
57.96
-6.00%
61.65
-41.94%
106.18
-37.29%
169.32
Total Debt
0.18
+14.29%
0.15
-60.71%
0.39
-29.37%
0.56
Capital Lease Obligations
0.18
+14.29%
0.15
-60.71%
0.39
-29.37%
0.56
Net Tangible Assets
57.96
-6.00%
61.65
-41.94%
106.18
-37.29%
169.32
Tangible Book Value
57.96
-6.00%
61.65
-41.94%
106.18
-37.29%
169.32
Investmentsin Joint Venturesat Cost
—
0.00
-100.00%
0.24
+696.67%
0.03
Non Current Accrued Expenses
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-29.81
+39.51%
-49.28
+18.22%
-60.27
-5.20%
-57.28
Cash Flow From Continuing Operating Activities
-29.81
+39.51%
-49.28
+18.22%
-60.27
-5.20%
-57.28
Net Income From Continuing Operations
-8.98
+84.46%
-57.77
+22.52%
-74.56
-11.87%
-66.65
Depreciation Amortization Depletion
0.09
-29.77%
0.13
-12.67%
0.15
-10.18%
0.17
Depreciation And Amortization
0.09
-29.77%
0.13
-12.67%
0.15
-10.18%
0.17
Other Non Cash Items
-0.57
+64.45%
-1.61
+47.81%
-3.09
-610.11%
-0.43
Stock Based Compensation
5.31
-33.52%
7.99
-26.80%
10.92
+14.96%
9.50
Operating Gains Losses
-21.48
-1059.18%
2.24
+9.70%
2.04
+89.86%
1.07
Change In Working Capital
-4.19
-1524.81%
-0.26
-106.03%
4.28
+556.94%
-0.94
Change In Prepaid Assets
-2.04
-175.00%
2.72
-53.19%
5.82
+225.27%
-4.64
Change In Payables And Accrued Expense
-1.30
+67.81%
-4.04
-162.13%
-1.54
-141.57%
3.71
Change In Accrued Expense
-1.15
+65.64%
-3.34
-131.74%
-1.44
-144.79%
3.22
Change In Payable
-0.15
+78.22%
-0.70
-605.05%
-0.10
-120.33%
0.49
Change In Account Payable
-0.15
+78.22%
-0.70
-605.05%
-0.10
-120.33%
0.49
Change In Other Working Capital
-0.85
-180.00%
1.06
—
—
Investing Cash Flow
47.27
+41.13%
33.49
+21.09%
27.66
+124.66%
-112.17
Cash Flow From Continuing Investing Activities
47.27
+41.13%
33.49
+21.09%
27.66
+124.66%
-112.17
Net PPE Purchase And Sale
—
0.00
+100.00%
-0.01
+77.78%
-0.05
Purchase Of PPE
—
0.00
+100.00%
-0.01
+77.78%
-0.05
Capital Expenditure
—
—
-0.01
+77.78%
-0.05
Net Investment Purchase And Sale
28.77
-18.95%
35.49
+18.62%
29.92
+126.76%
-111.82
Purchase Of Investment
-17.70
+63.83%
-48.93
+54.86%
-108.41
+46.15%
-201.32
Sale Of Investment
46.47
-44.96%
84.42
-38.97%
138.33
+54.56%
89.50
Net Business Purchase And Sale
18.50
+1025.00%
-2.00
+11.11%
-2.25
-650.00%
-0.30
Purchase Of Business
-1.50
+25.00%
-2.00
+11.11%
-2.25
-650.00%
-0.30
Gain Loss On Sale Of Business
-22.35
0.00
—
—
Financing Cash Flow
0.02
-99.69%
5.20
+3535.66%
0.14
-99.72%
51.08
Cash Flow From Continuing Financing Activities
0.02
-99.69%
5.20
+3535.66%
0.14
-99.72%
51.08
Net Common Stock Issuance
0.00
-100.00%
5.41
0.00
-100.00%
51.53
Proceeds From Stock Option Exercised
0.02
-74.19%
0.06
-78.01%
0.28
+18.49%
0.24
Net Other Financing Charges
—
-0.27
-92.81%
-0.14
+79.94%
-0.69
Changes In Cash
17.47
+264.96%
-10.59
+67.38%
-32.46
+72.58%
-118.38
Beginning Cash Position
13.90
-43.24%
24.49
-57.00%
56.96
-67.51%
175.33
End Cash Position
31.37
+125.66%
13.90
-43.24%
24.49
-57.00%
56.96
Free Cash Flow
-29.81
+39.51%
-49.28
+18.24%
-60.28
-5.13%
-57.34
Common Stock Issuance
0.00
-100.00%
5.41
0.00
-100.00%
51.53
Earnings Losses From Equity Investments
0.87
-60.96%
2.24
+9.70%
2.04
+89.86%
1.07
Issuance Of Capital Stock
0.00
-100.00%
5.41
0.00
-100.00%
51.53
Sale Of Business
20.00
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category